Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2014 Jul;2(4):579-587.
doi: 10.1111/j.2047-2927.2014.00216.x. Epub 2014 May 2.

Single, escalating dose pharmacokinetics, safety and food effects of a new oral androgen dimethandrolone undecanoate in man: a prototype oral male hormonal contraceptive

Prasanth Surampudi #  1 , Stephanie T Page #  1 , Ronald S Swerdloff  1 , Jean Jacques Nya-Ngatchou  1 , Peter Y Liu  1 , John K Amory  1 , Andrew Leung  1 , Laura Hull  1 , Diana L Blithe  1 , Jason Woo  1 , William J Bremner  1 , Christina Wang  1
Affiliations
Clinical Trial

Single, escalating dose pharmacokinetics, safety and food effects of a new oral androgen dimethandrolone undecanoate in man: a prototype oral male hormonal contraceptive

Prasanth Surampudi et al. Andrology. 2014 Jul.

Abstract

The novel androgen, dimethandrolone (DMA) has both androgenic and progestational activities, properties that may maximize gonadotropin suppression. We assessed the pharmacokinetics of dimethandrolone undecanoate (DMAU), an orally bioavailable, longer acting ester of DMA, for male contraceptive development. Our objective was to examine the safety and pharmacokinetics of single, escalating doses of DMAU (powder in capsule formulation) administered orally with or without food in healthy men. We conducted a randomized, double-blind Phase 1 study. For each dose of DMAU (25-800 mg), 10 male volunteers received DMAU and two received placebo at two academic medical centres. DMAU was administered both fasting and after a high-fat meal (200-800 mg doses). Serial serum samples were collected over 24 h following each dose. DMAU was well tolerated without significant effects on vital signs, safety laboratory tests or electrocardiograms. When administered while fasting, serum DMA (active compound) was detectable in only 4/10 participants after the 800 mg dose. When administered with a 50% fat meal, serum DMA was detectable in all participants given 200 mg DMAU and showed a dose-incremental increase up to 800 mg, with peak levels 4-8 h after taking the dose. Serum gonadotropins and sex hormone concentrations were significantly suppressed 12 h after DMAU administration with food at doses above 200 mg. This first-in-man study demonstrated that a single, oral dose of DMAU up to 800 mg is safe. A high-fat meal markedly improved DMAU/DMA pharmacokinetics.

Keywords: androgens; contraception; pharmacokinetics; progesterone/progestagens.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Serum DMAU (A) and DMA (B) concentrations after oral administration of a single dose 200, 400 or 800 mg of DMAU after fasting (closed circles) or a high fat meal (50% fat)(open circles). Note y axis is in log scale. (Conversion DMA 1 ng/ml =3.29 nmol/l and DMAU 1 ng/ml=2.12 nmol/l)
Fig. 1
Fig. 1
Serum DMAU (A) and DMA (B) concentrations after oral administration of a single dose 200, 400 or 800 mg of DMAU after fasting (closed circles) or a high fat meal (50% fat)(open circles). Note y axis is in log scale. (Conversion DMA 1 ng/ml =3.29 nmol/l and DMAU 1 ng/ml=2.12 nmol/l)
Fig. 2
Fig. 2
Serum LH (A), FSH (B), T(C), free T(D), DHT (E), and estradiol (F) concentrations after administration of a single dose 200, 400 or 800 mg of DMAU (n=10) or placebo after fasting (closed circles) or a high fat meal (50% fat, open circles). The right panel shows hormone levels in two participants taking the same number of capsules as the active drug studied while fasting or after a high fat meal on three occasions. Hormone concentrations at 12 or 24 h that were significantly different from baseline hormone concentration were marked with *(P<0.05) and **(P<0.001) at each dose level by mixed model analysis.
Fig. 2
Fig. 2
Serum LH (A), FSH (B), T(C), free T(D), DHT (E), and estradiol (F) concentrations after administration of a single dose 200, 400 or 800 mg of DMAU (n=10) or placebo after fasting (closed circles) or a high fat meal (50% fat, open circles). The right panel shows hormone levels in two participants taking the same number of capsules as the active drug studied while fasting or after a high fat meal on three occasions. Hormone concentrations at 12 or 24 h that were significantly different from baseline hormone concentration were marked with *(P<0.05) and **(P<0.001) at each dose level by mixed model analysis.
Fig. 2
Fig. 2
Serum LH (A), FSH (B), T(C), free T(D), DHT (E), and estradiol (F) concentrations after administration of a single dose 200, 400 or 800 mg of DMAU (n=10) or placebo after fasting (closed circles) or a high fat meal (50% fat, open circles). The right panel shows hormone levels in two participants taking the same number of capsules as the active drug studied while fasting or after a high fat meal on three occasions. Hormone concentrations at 12 or 24 h that were significantly different from baseline hormone concentration were marked with *(P<0.05) and **(P<0.001) at each dose level by mixed model analysis.
Fig. 2
Fig. 2
Serum LH (A), FSH (B), T(C), free T(D), DHT (E), and estradiol (F) concentrations after administration of a single dose 200, 400 or 800 mg of DMAU (n=10) or placebo after fasting (closed circles) or a high fat meal (50% fat, open circles). The right panel shows hormone levels in two participants taking the same number of capsules as the active drug studied while fasting or after a high fat meal on three occasions. Hormone concentrations at 12 or 24 h that were significantly different from baseline hormone concentration were marked with *(P<0.05) and **(P<0.001) at each dose level by mixed model analysis.
Fig. 2
Fig. 2
Serum LH (A), FSH (B), T(C), free T(D), DHT (E), and estradiol (F) concentrations after administration of a single dose 200, 400 or 800 mg of DMAU (n=10) or placebo after fasting (closed circles) or a high fat meal (50% fat, open circles). The right panel shows hormone levels in two participants taking the same number of capsules as the active drug studied while fasting or after a high fat meal on three occasions. Hormone concentrations at 12 or 24 h that were significantly different from baseline hormone concentration were marked with *(P<0.05) and **(P<0.001) at each dose level by mixed model analysis.
Fig. 2
Fig. 2
Serum LH (A), FSH (B), T(C), free T(D), DHT (E), and estradiol (F) concentrations after administration of a single dose 200, 400 or 800 mg of DMAU (n=10) or placebo after fasting (closed circles) or a high fat meal (50% fat, open circles). The right panel shows hormone levels in two participants taking the same number of capsules as the active drug studied while fasting or after a high fat meal on three occasions. Hormone concentrations at 12 or 24 h that were significantly different from baseline hormone concentration were marked with *(P<0.05) and **(P<0.001) at each dose level by mixed model analysis.
Fig. 2
Fig. 2
Serum LH (A), FSH (B), T(C), free T(D), DHT (E), and estradiol (F) concentrations after administration of a single dose 200, 400 or 800 mg of DMAU (n=10) or placebo after fasting (closed circles) or a high fat meal (50% fat, open circles). The right panel shows hormone levels in two participants taking the same number of capsules as the active drug studied while fasting or after a high fat meal on three occasions. Hormone concentrations at 12 or 24 h that were significantly different from baseline hormone concentration were marked with *(P<0.05) and **(P<0.001) at each dose level by mixed model analysis.
See this image and copyright information in PMC

References

    1. Anawalt BD, Herbst KL, Matsumoto AM, Mulders TM, Coelingh-Bennink HJ, Bremner WJ. Desogestrel plus testosterone effectively suppresses spermatogenesis but also causes modest weight gain and high-density lipoprotein suppression. Ferti Steril. 2000;74:707–714. - PubMed
    1. Attardi BJ, Hild SA, Koduri S, Pham T, Pessaint L, Engbring J, Till B, Gropp D, Semon A, Reel JR. The potent synthetic androgens, dimethandrolone (7alpha,11beta-dimethyl-19-nortestosterone) and 11beta-methyl-19-nortestosterone, do not require 5alpha-reduction to exert their maximal androgenic effects. J. Steroid Biochem. Mol. Biol. 2010 - PMC - PubMed
    1. Attardi BJ, Hild SA, Reel JR. Dimethandrolone undecanoate: a new potent orally active androgen with progestational activity. Endocrinology. 2006;147:3016–3026. - PubMed
    1. Attardi BJ, Marck BT, Matsumoto AM, Koduri S, Hild SA. Long-Term Effects of Dimethandrolone 17{beta}-Undecanoate (DMAU) and 11{beta}-Methyl-19-Nortestosterone 17{beta}-Dodecylcarbonate (11{beta}-MNTDC) on Body Composition, Bone Mineral Density, Serum Gonadotropins, and Androgenic/Anabolic Activity in Castrate Male Rats. J. Androl. 2010 - PubMed
    1. Attardi BJ, Pham TC, Radler LC, Burgenson J, Hild SA, Reel JR. Dimethandrolone (7alpha,11beta-dimethyl-19-nortestosterone) and 11beta-methyl-19-nortestosterone are not converted to aromatic A-ring products in the presence of recombinant human aromatase. J. Steroid Biochem. Mol. Biol. 2008;110:214–222. - PMC - PubMed

Publication types

LinkOut - more resources